OXLUMO
Total Payments
$3.8M
Transactions
4,372
Doctors
2,329
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $273,708 | 567 | 441 |
| 2023 | $719,730 | 1,268 | 761 |
| 2022 | $1.2M | 1,008 | 604 |
| 2021 | $626,280 | 1,311 | 880 |
| 2020 | $941,866 | 218 | 104 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.0M | 675 | 79.6% |
| Consulting Fee | $344,162 | 116 | 9.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $299,091 | 51 | 7.9% |
| Food and Beverage | $83,890 | 3,353 | 2.2% |
| Space rental or facility fees (teaching hospital only) | $24,950 | 13 | 0.7% |
| Travel and Lodging | $20,986 | 59 | 0.6% |
| Education | $2,208 | 105 | 0.1% |
Payments by Type
Research
$3.0M
675 transactions
General
$775,287
3,697 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study With an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1 | Alnylam Pharmaceuticals Inc. | $857,884 | 0 |
| A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels | Alnylam Pharmaceuticals Inc. | $697,153 | 0 |
| Computable Phenotype ofChildren with Primary HyperoxaluriaType 1 | Alnylam Pharmaceuticals Inc. | $349,363 | 0 |
| ILLUMINATE-B: An Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1 | Alnylam Pharmaceuticals Inc. | $342,482 | 0 |
| ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (PH1) | Alnylam Pharmaceuticals Inc. | $199,341 | 0 |
| A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (ILLUMINATE-C) | Alnylam Pharmaceuticals Inc. | $191,524 | 0 |
| A Retrospective Study of the Natural History of Patients with Advanced Primary Hyperoxaluria Type 1 (PH1) | Alnylam Pharmaceuticals Inc. | $156,000 | 0 |
| BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1) | Alnylam Pharmaceuticals Inc. | $123,992 | 0 |
| A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 | Alnylam Pharmaceuticals Inc. | $48,320 | 0 |
| Estimation of the Number of ESKD Events Avoided with Lumasiran Treatment in Patients with PH1 | Alnylam Pharmaceuticals Inc. | $25,452 | 0 |
| Expanded Access Protocol to Provide Lumasiran to Patients with Primary Hyperoxaluria Type 1 | Alnylam Pharmaceuticals Inc. | $20,315 | 0 |
| A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1 (ILLUMINATE-B) | Alnylam Pharmaceuticals Inc. | $14,412 | 0 |
Top Doctors Receiving Payments for OXLUMO
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $3.3M | 701 |
| Kyle Wood | Urology | Birmingham, AL | $51,474 | 29 |
| , M.D | Nephrology | Wilmington, DE | $37,430 | 46 |
| , M.D., M.S | Pediatric Nephrology | Cincinnati, OH | $20,450 | 15 |
| , MD | Diagnostic Radiology | St. Louis, MO | $19,030 | 7 |
| Michael Moritz | Pediatrics | Pittsburgh, PA | $18,333 | 8 |
| , M.D | Nephrology | New York, NY | $17,336 | 23 |
| , M.D., M.SC | Urology | Philadelphia, PA | $14,683 | 6 |
| , M.D | Nephrology | Los Angeles, CA | $11,530 | 8 |
| , MD SCD | Nephrology | Boston, MA | $11,070 | 6 |
| , MD | Nephrology | St Louis, MO | $10,530 | 3 |
| , M.D | Pediatric Nephrology | Detroit, MI | $10,510 | 14 |
| , M.D | Specialist | New York, NY | $9,634 | 17 |
| , M.D | Urology | Stony Brook, NY | $9,567 | 9 |
| , M.D | Nephrology | Rochester, MN | $9,045 | 9 |
| , DO | Pediatrics | Rochester, MN | $8,110 | 2 |
| , MD | Urology | Durham, NC | $7,255 | 2 |
| , MD | Pediatric Nephrology | Boston, MA | $6,750 | 3 |
| , M.D | Specialist | New York, NY | $5,950 | 11 |
| John Quigley | Hematology & Oncology | Chicago, IL | $5,792 | 10 |
| James Heubi | — | Cincinnati, OH | $5,650 | 3 |
| , M.D | Gastroenterology | Redwood City, CA | $5,400 | 1 |
| , M.D | Urology | Scottsdale, AZ | $4,848 | 4 |
| , MD, PHD | Pediatric Nephrology | Atlanta, GA | $4,800 | 3 |
| Mark White | Urology | Clifton Park, NY | $4,786 | 4 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $3.8M
- Total Doctors 2,329
- Transactions 4,372
About OXLUMO
OXLUMO is a drug associated with $3.8M in payments to 2,329 healthcare providers, recorded across 4,372 transactions in the CMS Open Payments database. The primary manufacturer is Alnylam Pharmaceuticals Inc..
Payment data is available from 2020 to 2024. In 2024, $273,708 was paid across 567 transactions to 441 doctors.
The most common payment nature for OXLUMO is "Unspecified" ($3.0M, 79.6% of total).
OXLUMO is associated with 12 research studies, including "ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study With an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1" ($857,884).